H.C. Wainwright analyst Matthew Caufield reiterated a Hold rating on Lyra Therapeutics (LYRA – Research Report) today and set a price ...
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback